Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StaphVAX Lot Consistency Study
NCT00211991Phase 3Completed
- Sponsor
- Nabi Biopharmaceuticals
- Start
- Apr 2005
- Primary completion
- Jul 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of s. aureus type 5 & 8 capsular polysaccharide vaccine in Staphylococcus aureus infection (3 arms), sponsored by Nabi Biopharmaceuticals. Primary endpoint: Type-specific antibody concentrations at 6 weeks. Started Apr 2005; status: completed.
02
Drugs
s. aureus type 5 & 8 capsular polysaccharide vaccine
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT00211991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211991.